ADC Therapeutics (ADCT) CAO reports 7,140 shares withheld for RSU tax and holds 70,757

Rhea-AI Filing Summary

ADC Therapeutics SA's Chief Accounting Officer reported a routine share transaction under Form 4. On 12/06/2025, the officer had 7,140 common shares disposed of at $3.29 per share, coded as an "F" transaction. This represents shares withheld by the company to cover tax obligations related to the vesting of previously granted restricted share units.

After this withholding event, the officer directly beneficially owns 70,757 common shares of ADC Therapeutics SA. The filing reflects administrative tax settlement activity rather than an open-market buy or sell decision.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kallebo Lisa Michelle

(Last) (First) (Middle)

430 MOUNTAIN AVENUE, SUITE 404

(Street)

NEW PROVIDENCE NJ 07974

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ADC Therapeutics SA [ ADCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/06/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	12/06/2025		F(1)		7,140	D(1)	$3.29	70,757	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted.

Remarks:

	/s/ Lisa Kallebo	12/09/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ADC Therapeutics (ADCT) report in this Form 4?

The Chief Accounting Officer reported that 7,140 common shares were disposed of on 12/06/2025, coded as an "F" transaction, meaning the shares were withheld by the company to cover tax obligations tied to vesting restricted share units.

Was the ADC Therapeutics (ADCT) Form 4 transaction an open-market sale?

No. The transaction is coded "F", and the explanation states it represents common shares withheld by the issuer to satisfy the reporting person's tax withholding obligations upon vesting of restricted share units, not an open-market sale.

How many ADC Therapeutics (ADCT) shares does the officer own after this transaction?

Following the reported tax withholding transaction, the Chief Accounting Officer directly beneficially owns 70,757 common shares of ADC Therapeutics SA.

What was the price used for the ADC Therapeutics (ADCT) share withholding?

The 7,140 common shares withheld to cover tax obligations were valued at $3.29 per share for this Form 4 transaction.

Who filed this ADC Therapeutics (ADCT) Form 4 and what is their role?

The Form 4 was filed by an officer of ADC Therapeutics SA serving as Chief Accounting Officer, reporting their beneficial ownership and the tax-related share withholding.

Does the ADC Therapeutics (ADCT) Form 4 indicate multiple reporting persons?

No. The filing indicates it is a Form filed by one reporting person, not a joint or group filing.